We can’t show the full text here under this license. Use the link below to read it at the source.
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States
Medication use, blood sugar control, and costs over 12 months in US patients with type 2 diabetes starting dulaglutide versus liraglutide or once-weekly exenatide
AI simplified
Abstract
Dulaglutide showed 51.2% adherence compared to 38.2% for liraglutide and 50.7% for exenatide once weekly.
- A higher proportion of patients initiating dulaglutide were adherent compared to those starting liraglutide and exenatide once weekly.
- At 12 months, 55% of patients on dulaglutide remained on treatment, significantly higher than 43.8% for liraglutide and 54.9% for exenatide.
- Dulaglutide treatment resulted in a greater reduction in HbA1c levels compared to liraglutide and a comparable reduction to exenatide.
- Diabetes-related costs were similar for dulaglutide and liraglutide, but dulaglutide was associated with higher costs than exenatide.
AI simplified
Key numbers
51.2%
Higher Adherence Rate
Proportion of patients with PDC ≥80% at 12 months
55%
Higher Persistence Rate
Proportion of patients persistent with index therapy at 12 months
-34.24 mmol/mol
Greater HbA1c Reduction
Change in HbA1c from baseline to 12 months for dulaglutide vs. liraglutide